Nathwani B N, Anderson J R, Armitage J O, Cavalli F, Diebold J, Drachenberg M R, Harris N L, MacLennan K A, Müller-Hermelink H K, Ullrich F A, Weisenburger D D
University of Southern California (USC) and Los Angeles County+USC Healthcare Network, Los Angeles, CA 90033, USA.
J Clin Oncol. 1999 Aug;17(8):2486-92. doi: 10.1200/JCO.1999.17.8.2486.
In the International Lymphoma Study Group classification of lymphoma, extranodal marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) type is listed as a distinctive entity. However, nodal MZL is listed as a provisional entity because of questions as to whether it is truly a disease or just an advanced stage of MALT-type MZL. To resolve the issue of whether primary nodal MZL without involvement of mucosal sites exists and whether it is clinically different from extranodal MALT-type lymphoma, we compared the clinical features of these two lymphomas.
Five expert hematopathologists reached a consensus diagnosis of MZL in 93 patients. Seventy-three were classified as having MALT-type MZL because of involvement of a mucosal site at the time of diagnosis, and 20 were classified as having nodal MZL because of involvement of lymph nodes without involvement of a mucosal site.
A comparison of the clinical features of nodal MZL and MALT-type MZL showed that more patients with nodal MZL presented with advanced-stage disease (71% v 34%; P =. 02), peripheral lymphadenopathy (100% v 8%; P <.001), and para-aortic lymphadenopathy (56% v 14%; P <.001) than those with MALT-type MZL. However, fewer patients with nodal MZL had a large mass (> or = 5 cm) than those with MALT-type MZL (31% v 68%; P =.03). The 5-year overall survival of patients with nodal MZL was lower than that for patients with MALT-type MZL (56% v 81%; P =.09), with a similar result for failure-free survival (28% v 65%; P =.01). Comparisons of patients with International Prognostic Index scores of 0 to 3 showed that those with nodal MZL had lower 5-year overall survival (52% v 88%; P =.025) and failure-free survival (30% v 75%; P =.007) rates than those with MALT-type MZL.
Nodal MZL seems to be a distinctive disease entity rather than an advanced stage of MALT-type MZL because the clinical presentations and survival outcomes are different in these two types of MZL. Clinically, nodal MZL is similar to other low-grade, node-based B-cell lymphomas, such as follicular and small lymphocytic lymphomas.
在国际淋巴瘤研究组的淋巴瘤分类中,黏膜相关淋巴组织(MALT)型结外边缘区B细胞淋巴瘤(MZL)被列为一种独特的实体。然而,结内MZL被列为一个暂定实体,因为存在它是否真的是一种疾病还是仅仅是MALT型MZL的晚期阶段的疑问。为了解决原发性结内MZL(无黏膜部位受累)是否存在以及它在临床上是否与结外MALT型淋巴瘤不同的问题,我们比较了这两种淋巴瘤的临床特征。
5位血液病理专家对93例患者达成了MZL的共识诊断。73例因诊断时黏膜部位受累而被分类为患有MALT型MZL,20例因淋巴结受累而无黏膜部位受累被分类为患有结内MZL。
结内MZL和MALT型MZL临床特征的比较显示,与MALT型MZL相比,更多结内MZL患者表现为晚期疾病(71%对34%;P = 0.02)、外周淋巴结肿大(100%对8%;P < 0.001)和腹主动脉旁淋巴结肿大(56%对14%;P < 0.001)。然而,结内MZL患者有大肿块(≥5 cm)的比MALT型MZL患者少(31%对68%;P = 0.03)。结内MZL患者的5年总生存率低于MALT型MZL患者(56%对81%;P = 0.09),无失败生存率也有类似结果(28%对65%;P = 0.01)。对国际预后指数评分为0至3分的患者进行比较显示,结内MZL患者的5年总生存率(52%对88%;P = 0.025)和无失败生存率(30%对75%;P = 0.007)低于MALT型MZL患者。
结内MZL似乎是一种独特的疾病实体,而非MALT型MZL的晚期阶段,因为这两种类型的MZL临床表现和生存结果不同。临床上,结内MZL与其他低级别、以淋巴结为基础的B细胞淋巴瘤,如滤泡性和小淋巴细胞淋巴瘤相似。